Compare Bristol-Myers Squibb Co (BMY) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Tesla, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Tesla, Inc. trades at $399.36 (market cap $1.49T). The key difference: Tesla, Inc. is far larger — about 12.8× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| BMY | TSLA | |
|---|---|---|
Market Cap | $116.30B | $1.49T |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $489.88 |
52-Week Low | $42.60 | $302.63 |
Enterprise Value | $152.24B | $1.46T |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Tesla (TSLA) trades at $394.76, down 3.18% over 24 hours, with a bearish technical outlook as it tests support near $391. The stock faces valuation concerns with a P/E of 363.47 and P/S of 14.3, while recent earnings show mixed results with a Q1 2026 beat but a Q3 2025 miss. Revenue declined to $94.83B in 2025, and net income margin compressed to 3.95%. Positive developments include regulatory approval for driver-assistance software in Europe (Reuters, 2026-04-10) and strong growth in German registrations (Zacks Investment Research, 2026-04-10).
Tesla's investment case balances high growth potential in autonomy and energy against near-term execution risks and rich valuations. The consensus price target of $409.26 implies modest upside, but competitive pressures and volatile cash flows warrant caution. Investors should focus on execution of the robotaxi and cheaper EV initiatives for catalysts, while monitoring margin recovery and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
